Recent Scientific Publications

Journal Articles

1. O'Brien SF, Xi G, Yi Q.-L., Goldman M.  Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use.  Transfusion Medicine, Volume 20 Issue 1, Pages 15 – 21 (Published Online: 30 Sep 2009)
   View abstract >
   
   
2. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, and Metzel P. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results.   Transfusion (Published Online: 19Nov2009)
   View abstract >
   
   
3. Irsch J, Pinkoski L, Corash L, Lin L.  INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sanguinis 2010: 98, 47–55
   View abstract >
   
   
4. Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash DM, Lin L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals. 2009 Dec 6. [Epub ahead of print]
   View abstract >
   
   
5. Wendel S. Transfusion transmitted Chagas disease: Is it really under control?  Acta Trop. 2009 Dec 29. [Epub ahead of print]
   View abstract >
   
   
6. JP Cazenave, C Waller, D Kientz, I Mendel, L Lin, M Jacquet, M Propst, W Liu, L Corash, D Sundin, L Defoin, N Messe, and JCOsselaer. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
   > View abstract
   
   
7. Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang J-H, Champion M, Fang C, Dodd R. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.  Transfusion 2009 Nov 13. [Epub ahead of print]
   > Read abstract
   

Conference Abstracts

12th International Haemovigilance Seminar
February 17 - 19, 2010 | Dubrovnik, Croatia

1. JC Osselaer, JP Cazenave, W Liu, A Elliot, W Reed, L Lin, L Corash. An Active Hemovigilance Program to Assess the Safety Outcome for 18,641 Platelet Components Tranfused in Multiple European Clinical Sites.
   [Abstract PDF]
   
   
2. JP Cazenave, JC Osselaer, W Liu, A Elliot, W Reed, L Lin, L Corash. An Active Hemovigilance Program to Assess the Safety Outcome for 32, 480 INTERCEPT Plasma Component Transfusions.
   [Poster PDF]
   
   
3. D Domanovic, A Milojkovic, M Cukjati, J Irsch, L Lin. Hemovigilance of Transfusions with Platelet Treated with INTERCEPT Blood System Using an Active Hemovigilance Program - Data from Slovenia.
   [Abstract PDF]
   
   
4. F Knutson, H Lof. HV at a University Hospital After Transfusions of Platelets Pathogen Inactivated with the INTERCEPT Technology.
   [Abstract PDF]
   
   
5. JC Osselaer, B De Coene, MC Thonet, C Corlier, J Jamart, C Doyen. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components: A Six-year Hemovigilance Survey.
   [Poster PDF]
   
   
6. JP Cazenave, D Kientz, I Mendel, H Isola, C Waller. Hemovigilance Surveillance Of Platelet Components Prepared With Pathogen Inactivation Treatment During a Three Year Period.
   [Abstract PDF] [Poster PDF]
   
   
7. D Kientz, I Mendel, C Waller, H Isola, JP Cazenave. Hemovigilance Surveillance Of Therapeutic Plasma Prepared With Pathogen Inactivation Treatment During a Two Year Period.
   [Poster PDF]
   
   

XXth Regional Congress, Asia, International Society Blood Transfusion
November 14 - 18, 2009 | Nagoya, Japan

1. L Lin and L Corash. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with INTERCEPT Blood System Transfused in Routine Clinical Practice.
   [Poster PDF]
   
   
2. JP Cazenave, A. Shimosaka, L Corash. Active Hemovigilance of Pediatric Patients Supported with Plasma Components Prepared with Photochemical Treatment (INTERCEPT™).
   [Poster PDF]
   
   
3. A Shimosaka, JC Osselaer, W Liu, L Lin. Pathogen Inactivation and In Vitro Function of Platelet Components Collected in 100% Plasma Treated with INTERCEPT Blood System
   [Poster PDF]

2009 AABB Annual Meeting & TXPO
October 24 - 27, 2009 | New Orleans, USA

1. H Isola, D Kientz, F Bigey, S Somme, C Forny, J Cazenave. The Impact of Replacing Quarantine Plasma by Plasma Prepared with Pathogen Inactivation (INTERCEPT™) – Experience in EFS-Alsace. Transfusion 2009; 49(suppl 1):81A
   [Poster PDF]
   
   
2. L Sawyer, R Mababangloob, N Patel, J Kinsey, A Sampson-Johannes, D Hanson. Pathogen Inactivation Achieved with Amotosalen and UVA in Platelets Suspended in
   Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol. Transfusion 2009; 49(suppl 1):95A
   [Poster PDF]
   
   
3. RE Agliastro, G DeFrancisci, M Diquattro, R Bonaccorso, M Tagliavia, M Marcatti, B Palma. Should the Use of Pathogen Inactivated Platelet Concentrates Be Extended to 7 Days?
   In Vitro Study on the Quality of Platelets at 3, 5 and 7 Days. Transfusion 2009; 49(suppl 1):96A
   
   
4. D P Brilhante, S Rodrigues, M Santos, L Castro. Platelet Components Treated with Pathogen Inactivation: Clinical Outcomes of the First Single Center Observational Study in Lisbon, Portugal. Transfusion 2009; 49(suppl 1):97A
   
   
5. L Defoin, L Bouchat, M Goffaux, S Vanden Bossche, P Paternostre, M Vandendaele, M van Hooydonk, JC Osselear. Transfusion Efficacy Determined by the CCI at 24 Hours Is Not Influenced by the Collected Platelet Yield with Amicus®. Transfusion 2009; 49(suppl 1):162A
   
   
6. E Girona-Llobera, TM Jimenez-Marco, M Sedeño, J Muncunill. The Impact of the Platelet Pathogen Inactivation Technology on the Platelet Inventory Management. Transfusion 2009; 49(suppl 1):266A
   
   

42nd Annual Congress of the German Society for Transfusion Medicine and Immunohaematology (DGTI)
September 15 - 18, 2009 | Rostock, Germany

1. M Deane, P Rivera, L Sawyer. INTERCEPT Platelets Treated and Stored in SSP+ Meet Council of Europe Standards for In Vitro function After 7 Days of Storage. Transfus Med Hemother 2009;36(suppl 1):1-62
   
   
2. R Henschler, M Wiesneth, H.-U Pfeiffer, M Muller, S Andresen, A Kramer, J Irsch, L Lin, L Corash, H Schrezenmeier, E Seifried. Double-Dose Platelet Concentrates Prepared from Pools of 7 or 6 Buffy Coats for Pathogen-Inactivation with the INTERCEPT System. Transfus Med Hemother 2009;36(suppl 1):1-62
   
   
3. C Lehmann, S Rummler, C Kummer, D Barz. A New Cell Free, Pathogen Inactivated Single Donor Plasma. Transfus Med Hemother 2009;36(suppl 1):1-62
   

6th IABS symposium on Advances in Transfusion Safety (IABS)
July 6 - 7, 2009 | Cambridge, UK

1. L Lin, N Mufti. Pathogen Inactivation of Red Blood Cell Concentrates (RBC) and Whole Blood (WB) Using the INTERCEPT Technology: Advances and Challenges
   [Presentation PDF]
   

24th Société Français de Transfusion Sanguine (SFTS)
June 22 - 25, 2009 | Strasbourg, France

1. S Massard, C Civadier, I Ernou, S Dhuguet, A Sanchez, C Antoinette, M Slaedts, M Joussemet. Mise en place du procede INTERCEPT sure le plasma au CTSA

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
June 11 - 13, 2009 | Tarragona, Spain

1. E Girona-Llobera, MT Jiménez-Marco, M Sedeño, N Serra, J Muncunill. Implantación en un centro de transfusión del sistema INTERCEPT de inactivatión de patógenos de componentes plaquetarios.
   
   
2. A Pajares, L Barea, P Rodriguez, F Surribas , I Diaz, L Lopez, E Castro. Mejora en la eficiencia del sistema INTERCEPT para plasma mediante un dispositivo para mezclar 5 PFC.

14th Annual Congress of the European Hematology Association (EHA)
June 4 - 7, 2009 | Berlin, Germany

1. JP Cazenave, I Mendel, C Waller, JC Osselaer, M Jacquet, M Propst, L Lin, L Corash, D Kientz. Active Hemovigilance of Pediatric Patients Supported with Plasma Components Prepared with Amotosalen Plus UVA Photochemical Treatment.
   [Poster PDF]
   
   
2. P Cazenave, ML Wiesel, I Mendel, A Faradji, S Mangin, B Perricard, D Kientz. Transfusion of Platelet Components Prepared with Photochemical Pathogen Inactivation for Support of Severe Glanzmann Thrombasthenia During Surgical Procedures.
   [Poster PDF]
   
   
3. D Kientz, ML Wiesel, I Lanois, T Krummel, B Moulin, R Herbrecht, JP Cazenave. Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) Using Plasma Prepared with Photochemical Pathogen Inactivation: A One Year Experience in Routine Practice in a Regional Blood Center.
   [Poster PDF]
   
   
4. JC Osselaer, JP Cazenave, P Rasongles, F Knutson, L Lin and L Corash on behalf of the INTERCEPT Platelet Hemovigilance Study Group. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with Photochemical Pathogen Inactivation Treatment Transfused In Routine Clinical Practice.
   
   
Return to top